Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat Combined With CD30 Target Immunotherapy for CD30+ Lymphoma
NCT07138547Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eliglustat in lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoints: Number of Subjects with treatment-related adverse events at 120 days, Complete Response Rate at 12 months and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
eliglustat
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT07138547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138547.